Coveram (perindopril arginine+amlodipine) / Servier - LARVOL DELTA

Evaluation of the Antihypertensive effectIveness, Tolerability, and Adherence With Amlodipine/ Indapamide/ Perindopril Triple Single-pill Combination in Hypertensive Patients Without Concomitant Antihypertensive Therapy (TRIPTYCH) (clinicaltrials.gov) - P=N/A | N=396 | Completed | Sponsor: Servier Russia | Not yet recruiting ➔ Completed | Trial completion date: Feb 2025 ➔ Jun 2025 | Trial primary completion date: Dec 2024 ➔ Apr 2025

Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension

Simplified Approach to Managing Newly Diagnosed Patients with Mild-to-Moderate Hypertension in Routine Clinical Practice. (PubMed, Adv Ther) - "Data from routine Canadian clinical practice indicate that a perindopril/amlodipine SPC is associated with significant BP reductions from baseline in a broad range of participants with different cardiovascular risk factors and may represent an appropriate first-line treatment for subjects with newly diagnosed hypertension."

Journal • Cardiovascular • Diabetes • Hypertension • Metabolic Disorders

EDUHYPER: Observational Cohort Study Evaluating the Effectiveness of an Educational Program (NGAYDAUTIEN) in Combination With Perindopril and Amlodipine Single-Pill Combination in Hypertensive Patients naïve of Antihypertensive Treatments. (clinicaltrials.gov) - P=N/A | N=400 | Completed | Sponsor: Servier Affaires Médicales

Combination therapy • New trial • Cardiovascular • Hypertension

Cost-effectiveness analysis comparing single-pill combination of perindopril/amlodipine/indapamide to the free equivalent combination in patients with hypertension from an Italian national health system perspective. (PubMed, Expert Rev Pharmacoecon Outcomes Res) - "Results were robust to sensitivity and scenario analyses, indicating that use of this SPC is a cost-effective strategy. The findings indicate that a perindopril/amlodipine/indapamide SPC is a cost-saving treatment option for hypertension in Italy, compared to its FEC."

Cost effectiveness • HEOR • Journal • Cardiovascular • Hypertension

Description of the Effectiveness, Safety, Tolerability and Adherence to Amlodipine/Atorvastatin/Perindopril Single Pill Combination Treatment in Patients With Arterial Hypertension and Dyslipidemia (TARGET) (clinicaltrials.gov) - P=N/A | N=409 | Completed | Sponsor: Servier Russia | Not yet recruiting ➔ Completed

Adherence • Trial completion • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders • Pulmonary Arterial Hypertension

Evaluation of the Antihypertensive effectIveness, Tolerability, and Adherence With Amlodipine/ Indapamide/ Perindopril Triple Single-pill Combination in Hypertensive Patients Without Concomitant Antihypertensive Therapy (TRIPTYCH) (clinicaltrials.gov) - P=N/A | N=375 | Not yet recruiting | Sponsor: Servier Russia

Adherence • New trial • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension

Efficacy and safety of perindopril/indapamide/amlodipine single-pill combination in essential hypertension (ESC 2023) - "Perindopril/Indapamide/Amlodipine SPC is as effective and safe as the free combination in hypertensive patients uncontrolled with dual therapy of Perindopril/Indapamide. The uptitration to higher dosages of the triple-drug SPC provided additional benefit on BP lowering and BP control without increasing pill burden."

Clinical • Cardiovascular • Hypertension • Hypotension

Lethal Toxic Epidermal Necrolysis probably induced by the Sinopharm COVID-19 vaccine (WCD 2023) - "His usual medication included the combination of Perindopril and Amlodipine (Coveram*) for more than two years...To our knowledge, this is the first case of TEN reported with the Sinopharm vaccine. Therefore, this is an exceedingly rare adverse effect of the vaccine, and the benefits far outweigh the risks"

Cardiovascular • Critical care • Hematological Disorders • Human Immunodeficiency Virus • Hypertension • Infectious Disease • Novel Coronavirus Disease • Pain • Respiratory Diseases • Steven-Johnson Syndrome • Thrombocytopenia

Description of the Effectiveness, Safety, Tolerability and Adherence to Amlodipine/Atorvastatin/Perindopril Single Pill Combination Treatment in Patients With Arterial Hypertension and Dyslipidemia in the Daily Clinical Practice. (TARGET) (clinicaltrials.gov) - P=N/A | N=400 | Not yet recruiting | Sponsor: Servier Russia

New trial • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders • Pulmonary Arterial Hypertension

[VIRTUAL] Effectiveness and Tolerability of Perindopril 3.5 Mg/amlodipine 2.5 Mg Single Pill Combination in Newly Diagnosed Patients With Hypertension. The Simple National Study Across Canada (AHA 2020) - "The Canadian SIMPLE study confirms the early benefits, tolerability of and compliance to the SPC perindopril/amlodipine 3.5 mg/2.5 mg, with a possibility of up-titration. This supports the guidelines recommendation for SPC use in newly diagnosed patients with hypertension as a first-line therapeutic option in clinical practice."

Clinical • Hypertension • Metabolic Disorders

Short-term effects of perindopril-amlodipine vs perindopril-indapamide on blood pressure control in sub-Saharan type 2 diabetic individuals newly diagnosed for hypertension: A double-blinded randomized controlled trial. (PubMed, J Clin Hypertens (Greenwich)) - "A fixed initial combination of perindopril-amlodipine or perindopril-indapamide achieved similar effective BP control after 6 weeks in SSA type 2 diabetic individuals with newly diagnosed hypertension. Therefore, these combinations can be used interchangeably in this indication."

Clinical • Journal • Diabetes • Hypertension • Metabolic Disorders • Type 2 Diabetes Mellitus

Treatment of Hypertensive and Hypercholesterolaemic Patients with the Triple Fixed Combination of Atorvastatin, Perindopril and Amlodipine: The Results of the CORAL Study. (PubMed, Adv Ther) - "Treatment with the fixed triple combination of atorvastatin, perindopril and amlodipine might take us closer to the optimal therapy for hypertensive patients with hypercholesterolaemia. The expected improvement of patient adherence to treatment may result in an increase of the percentage patients who achieve both blood pressure control and the LDL-cholesterol targets recommended in guidelines. Moreover, this may translate into the further decline of the risk of prospective cardiovascular events."

Clinical • Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Hypertension • Immunology

Fixed-Dose Triple Combination of Antihypertensive Drugs Improves Blood Pressure Control: From Clinical Trials to Clinical Practice. (PubMed) - "FDTC of perindopril/indapamide/amlodipine was effective at reducing SBP and PP in previously treated patients with uncontrolled hypertension, and well tolerated, providing support for clinicians in choosing a fixed-dose triple combination over the free-combination of a RAAS inhibitor, a diuretic, and a calcium antagonist."

Journal • Biosimilar • Cardiovascular

Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: Case report of severe multiorgan involvement to perindopril/amlodipine combination antihypertensive. (PubMed, JAAD Case Rep) - No abstract available.

Clinical • Journal • Biosimilar • Renal Disease

SINGLE-PILL TRIPLE COMBINATION OF PERINDOPRIL/INDAPAMIDE/AMLODIPINE IN PATIENTS WITH ESSENTIAL HYPERTENSION: SERBIAN EXPERIENCE. (ISHyp 2016) - "There was a higher proportion of patients achieving target blood pressure (<140/90 mmHg) in the single-pill triple combination group (69.7%) in comparison with the other group (50%). Our results showed significant reductions in blood pressure and a high BP control rate with the single-pill triple combination perindropil/amlodipine/indapamide in patients with uncontrolled essential hypertension without comorbidities."

Clinical • Biosimilar • Cardiovascular

The Antihypertensive Efficacy of the Triple Fixed Combination of Perindopril, Indapamide, and Amlodipine: The Results of the PETRA Study. (PubMed, Adv Ther) - "During the 3 months of the PETRA study, the outstanding 24-h antihypertensive efficacy of the triple fixed combination of perindopril, indapamide, and amlodipine was confirmed both by office BP readings and by ABPM recordings. This combination may offer a new therapeutic option for hypertensive patients who have failed to achieve the desired BP target on their previous dual combination therapy."

Journal • Biosimilar • Cardiovascular

A Validated HPLC Method for Simultaneous Determination of Perindopril Arginine, Amlodipine, and Indapamide: Application in Bulk and in Different Pharmaceutical Dosage Forms. (PubMed) - J AOAC Int - "The results showed that there was no significant difference between the methods. The developed method proved reliable for use in accurate QC of the drugs in their pharmaceutical preparations."

Journal • Acute Myelogenous Leukemia • Biosimilar • Hematological Malignancies • Leukemia

Treatment with Free Triple Combination Therapy of Atorvastatin, Perindopril, Amlodipine in Hypertensive Patients: A Real-World Population Study in Italy. (PubMed, High Blood Press Cardiovasc Prev) - "Real-world analysis among patients with free combination therapy can be applied to estimate the eligible population for fixed combination, and to evaluate the appropriateness of their prescriptions. Moreover, fixed-dose CTAPA could effectively improve adherence, which was calculated to be low in the free combination cohort."

Clinical • Combination therapy • Journal • Real-World Evidence • Retrospective data

Efficacy and Safety of Incremental Dosing of a New Single-Pill Formulation of Perindopril and Amlodipine in the Management of Hypertension. (PubMed, Am J Cardiovasc Drugs) - P3; "Incremental uptitration with dosage-adapted perindopril/amlodipine SPC is a safe and effective strategy for managing hypertension."

Clinical • Journal

Antihypertensive Effect of Switching to a Fixed Perindopril/Amlodipine Combination in Patients Ineffectively Treated by Free Sartan-Containing Combinations. Results of the AVANGARD Study (PubMed, Kardiologiia) - "In case of ineffective combination therapy containing sartans, transfer of patients to a fixed combination of perindopril and amlodipine should be considered."

Clinical • Journal

One-year persistence of fixed-dose combinations of angiotensin-converting enzyme inhibitor and calcium channel blocker in hypertensive patients (PubMed, Orv Hetil) - "The authors demonstrated that the one-year persistence of ACEI/CCB FDCs was significantly different in hypertensive patients. Ramipril/amlodipine FDC was more advantageous for patient adherence. Orv Hetil. 2019; 160(9): 343-348."

Clinical • Journal

Modifications in drug adherence after switch to fixed-dose combination of perindopril/amlodipine in clinical practice. Results of a large-scale Italian experience. The amlodipine-perindopril in real settings (amperes) study. (PubMed, Curr Med Res Opin) - "Our results show that, perindopril/amlodipine FDC increases the rate of stay-on-therapy and reduces the number of concomitant antihypertensive drugs in subjects previously treated with the same drugs as a two-pill combination or as SPT."

Clinical • Journal

Assessment of Efficacy of Combined Pharmacotherapy With Fixed Perindopril/Amlodipine Combination in Patients With Combined Cardiovascular Pathology in Outpatient Practice (PubMed, Kardiologiia) - "The study included 50 patients aged 45-65 years with combined cardiovascular pathology: II-III degree arterial hypertension, I-III functional class (FC) stable angina pectoris, I-III FC chronic cardiac failure. Number of patients who reached target level of office BP by the end of active observation was 41 (p."

Clinical • Journal

Efficacy and Safety of a Fixed Combination of Perindopril Arginine and Amlodipine in Patients With Hypertension Uncontrolled by Treatment With Angiotensin II Receptor Blockers in Real Clinical Practice. Results of the PREVOSHODSTVO (SUPERIORITY) Program (PubMed, Kardiologiia) - "In patients, whose hypertension was not controlled by treatment with ARBs the fixed-dose combination of perindopril/amlodipine provided high percentage of achievement of target BP and reduction of long-term BP variability."

Clinical • Head-to-Head • Journal

24‑Hour Arterial Pressure Variability: Prognostic Significance, Methods of Evaluation, Effect of Antihypertensive Therapy (PubMed, Kardiologiia) - "We discuss in this article problems of prognostic significance of 24‑hour arterial pressure variability (24hAPV), as well as the role of 24hAPV in development and progression of various target organs damage by arterial hypertension. We also present literature data on impact of various regimens of antihypertensive therapy on 24hAPV, and on ability of fixed-dose perindopril/amlodipine to lower 24‑hAPV."

Journal